Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.42
ELGX's Cash to Debt is ranked lower than
72% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. ELGX: 0.42 )
Ranked among companies with meaningful Cash to Debt only.
ELGX' s Cash to Debt Range Over the Past 10 Years
Min: 0.42  Med: No Debt Max: No Debt
Current: 0.42
Equity to Asset 0.37
ELGX's Equity to Asset is ranked lower than
81% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ELGX: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
ELGX' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.85 Max: 0.96
Current: 0.37
0.31
0.96
F-Score: 2
Z-Score: 0.45
M-Score: -2.53
WACC vs ROIC
5.86%
-54.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -54.29
ELGX's Operating margin (%) is ranked lower than
81% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. ELGX: -54.29 )
Ranked among companies with meaningful Operating margin (%) only.
ELGX' s Operating margin (%) Range Over the Past 10 Years
Min: -126.68  Med: -21.37 Max: -4.47
Current: -54.29
-126.68
-4.47
Net-margin (%) -82.39
ELGX's Net-margin (%) is ranked lower than
82% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. ELGX: -82.39 )
Ranked among companies with meaningful Net-margin (%) only.
ELGX' s Net-margin (%) Range Over the Past 10 Years
Min: -119.57  Med: -32.34 Max: 15.84
Current: -82.39
-119.57
15.84
ROE (%) -119.43
ELGX's ROE (%) is ranked lower than
93% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.61 vs. ELGX: -119.43 )
Ranked among companies with meaningful ROE (%) only.
ELGX' s ROE (%) Range Over the Past 10 Years
Min: -119.43  Med: -35.43 Max: 15.58
Current: -119.43
-119.43
15.58
ROA (%) -44.21
ELGX's ROA (%) is ranked lower than
86% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. ELGX: -44.21 )
Ranked among companies with meaningful ROA (%) only.
ELGX' s ROA (%) Range Over the Past 10 Years
Min: -44.21  Med: -19.49 Max: 11.48
Current: -44.21
-44.21
11.48
ROC (Joel Greenblatt) (%) -278.27
ELGX's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.27 vs. ELGX: -278.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ELGX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -278.27  Med: -105.62 Max: -21.18
Current: -278.27
-278.27
-21.18
Revenue Growth (3Y)(%) 8.60
ELGX's Revenue Growth (3Y)(%) is ranked higher than
68% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ELGX: 8.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ELGX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.3  Med: 15.1 Max: 68.4
Current: 8.6
-41.3
68.4
EBITDA Growth (3Y)(%) 7.40
ELGX's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. ELGX: 7.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ELGX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.1  Med: -6.7 Max: 77.9
Current: 7.4
-51.1
77.9
EPS Growth (3Y)(%) 7.70
ELGX's EPS Growth (3Y)(%) is ranked higher than
54% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. ELGX: 7.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ELGX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.6  Med: 4 Max: 128.9
Current: 7.7
-51.6
128.9
» ELGX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ELGX Guru Trades in Q3 2015

Paul Tudor Jones 20,341 sh (New)
Steven Cohen 573,100 sh (New)
Pioneer Investments 801,248 sh (+22.82%)
Jim Simons Sold Out
» More
Q4 2015

ELGX Guru Trades in Q4 2015

Pioneer Investments 843,312 sh (+5.25%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q1 2016

ELGX Guru Trades in Q1 2016

Paul Tudor Jones 20,724 sh (New)
Jim Simons 341,622 sh (New)
Pioneer Investments 720,793 sh (-14.53%)
» More
Q2 2016

ELGX Guru Trades in Q2 2016

Columbia Wanger 1,149,943 sh (New)
Paul Tudor Jones 26,571 sh (+28.21%)
Pioneer Investments 719,624 sh (-0.16%)
Jim Simons 79,322 sh (-76.78%)
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:LMNX, NYSE:GKOS, NAS:MMSI, NAS:ATRI, NAS:NVCR, OTCPK:NNCSF, NAS:ANGO, NAS:ATRC, OTCPK:TOPCF, NAS:NXTM, NAS:OSUR, NAS:MLAB, NAS:STAA, NAS:CFMS, NAS:ENTL, NAS:LMAT, AMEX:CRHM, NYSE:HYH, NAS:UTMD, NAS:IVTY » details
Traded in other countries:RM1.Germany,
Endologix Inc develops, manufactures, markets & sells medical devices for the treatment of aortic disorders. Its EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System.

Endologix Inc was incorporated in California on March 16, 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells medical devices for the treatment of abdominal aortic aneurysms (AAA). Its main products are intended for the treatment of AAA through minimally-invasive endovascular repair (EVAR) or endovascular sealing ('EVAS'), solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The Company's EVAR products consist of: a cobalt chromium alloy stent covered by polytetrafluoroethylene graft material; and an accompanying delivery system. The Company's EVAS product consists of: bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. Its main competitors include: Medtronic, Inc., W.L. Gore Inc., and Cook Medical Products, Inc., and new market entrants, TrvVascular, Inc. and Lombard Medical Technologies. The Company is subject to additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Guru Investment Theses on Endologix Inc

Meridian Funds Comments on Endologix Inc - Dec 17, 2014

Endologix (ELGX) is a medical device company with products that treat aortic abdominal aneurisms (AAA). Recently the company experienced a decline in sales growth after the conclusion of a clinical trial rollout. We believed the revenue issue was temporary and were very excited about a new product called Nellix that has the potential to more than double Endologix’s market share in AAA procedures. During the quarter, share performance disappointed after the company disclosed that sales would again miss expectations, this time due to an intensifying competitive environment. While management outlined an aggressive response, including product enhancements intended to further improve upon the lowest complication rate in the AAA industry, we have reduced our position until we can gain greater clarity on how effective these efforts will be in the market.

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/B 6.57
ELGX's P/B is ranked lower than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. ELGX: 6.57 )
Ranked among companies with meaningful P/B only.
ELGX' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 5.68 Max: 14.18
Current: 6.57
1.69
14.18
P/S 4.92
ELGX's P/S is ranked lower than
70% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ELGX: 4.92 )
Ranked among companies with meaningful P/S only.
ELGX' s P/S Range Over the Past 10 Years
Min: 1.14  Med: 6.32 Max: 33.73
Current: 4.92
1.14
33.73
Current Ratio 2.63
ELGX's Current Ratio is ranked higher than
54% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ELGX: 2.63 )
Ranked among companies with meaningful Current Ratio only.
ELGX' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 5.88 Max: 20.25
Current: 2.63
2.15
20.25
Quick Ratio 1.92
ELGX's Quick Ratio is ranked higher than
58% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. ELGX: 1.92 )
Ranked among companies with meaningful Quick Ratio only.
ELGX' s Quick Ratio Range Over the Past 10 Years
Min: 1.92  Med: 4.6 Max: 19.04
Current: 1.92
1.92
19.04
Days Inventory 206.60
ELGX's Days Inventory is ranked lower than
79% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.07 vs. ELGX: 206.60 )
Ranked among companies with meaningful Days Inventory only.
ELGX' s Days Inventory Range Over the Past 10 Years
Min: 168.66  Med: 239.82 Max: 482.28
Current: 206.6
168.66
482.28
Days Sales Outstanding 77.05
ELGX's Days Sales Outstanding is ranked lower than
71% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. ELGX: 77.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.06  Med: 67.04 Max: 77.86
Current: 77.05
58.06
77.86
Days Payable 80.29
ELGX's Days Payable is ranked higher than
67% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.53 vs. ELGX: 80.29 )
Ranked among companies with meaningful Days Payable only.
ELGX' s Days Payable Range Over the Past 10 Years
Min: 69.82  Med: 123.89 Max: 288.83
Current: 80.29
69.82
288.83

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
ELGX's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. ELGX: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.1  Med: -9.9 Max: -2.8
Current: -2.8
-35.1
-2.8

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.79
ELGX's Price/Median PS Value is ranked higher than
79% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. ELGX: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
ELGX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.06 Max: 7.97
Current: 0.79
0.22
7.97
Earnings Yield (Greenblatt) (%) -13.18
ELGX's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. ELGX: -13.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ELGX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.23  Med: 0 Max: 0
Current: -13.18
-13.23
0

More Statistics

Revenue (TTM) (Mil) $170.8
EPS (TTM) $ -1.82
Beta0.58
Short Percentage of Float19.34%
52-Week Range $6.51 - 14.50
Shares Outstanding (Mil)82.37

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 201 223 266
EPS ($) -0.74 -0.58 -0.26
EPS w/o NRI ($) -0.74 -0.58 -0.26
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ELGX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Endologix Inc Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 
Endologix Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Endologix Inc Reports Operating Results (10-Q) Jul 30 2010 
Weekly CEO Sells Highlight: Cisco Systems Inc, AmerisourceBergen Corp, PAETEC HOLDING CORP, Endologi May 22 2010 
Endologix Inc (ELGX) CEO John D Mcdermott sells 225,000 Shares May 17 2010 
Endologix Inc Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
Endologix's Ovation Alto System Treats First Patients Aug 22 2016
Endologix Announces First Patients Treated with Ovation Alto™ Abdominal Stent Graft System Aug 17 2016
Endologix Announces First Patients Treated with Ovation Alto™ Abdominal Stent Graft System Aug 17 2016
ENDOLOGIX INC /DE/ Financials Aug 16 2016
Endologix, Inc. :ELGX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 Aug 09 2016
ETF’s with exposure to Endologix, Inc. : August 5, 2016 Aug 05 2016
ENDOLOGIX INC /DE/ Files SEC form 10-Q, Quarterly Report Aug 05 2016
Endologix to Present at the 36th Annual Canaccord Genuity Growth Conference Aug 04 2016
Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : August 4, 2016 Aug 04 2016
Why Endologix (ELGX) Stock Is Tumbling Today Aug 03 2016
Analysts' Actions -- Bruker, Endologix, Mosaic, Trex and More Aug 03 2016
Endologix downgraded by RBC Capital Mkts Aug 03 2016
Endologix reports 2Q loss Aug 02 2016
Endologix reports 2Q loss Aug 02 2016
Endologix Inc Earnings Call scheduled for 5:00 pm ET today Aug 02 2016
Endologix Reports Results for the Second Quarter 2016 Aug 02 2016
ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition Aug 02 2016
Endologix Reports Results for the Second Quarter 2016 Aug 02 2016
Q2 2016 Endologix Inc Earnings Release - After Market Close Aug 02 2016
Coverage Initiated on Select Healthcare Stocks Jul 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)